ReviewTherapeutic advances in gastroenterology2025
A targeted review of clinical outcomes of advanced IBD therapies in Latin America.
Review in Therapeutic advances in gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There exists a significant care gap in the diagnosis, treatment, and management of inflammatory bowel diseases (IBD) in Latin America compared to the United States and Europe. This review aims to assess the clinical effectiveness of advanced therapies for patients with moderate to severe ulcerative colitis (UC) and Crohn's disease (CD) in Latin America. We conducted a targeted literature review of studies reporting clinical outcomes of advanced IBD therapies in Latin American countries. After applying pre-defined inclusion and exclusion criteria, 14 articles were included. Data were extracted regarding patient populations, therapeutic agents, clinical outcomes, and geographic distribution. The majority of studies focused on biologic therapies, including adalimumab, infliximab, ustekinumab, and vedolizumab. These therapies demonstrated favorable clinical remission and response rates in Brazil, Argentina, Mexico, and Colombia for both UC and CD. Reported outcomes were largely consistent with observational data from North America and Europe, supporting the generalizability of therapeutic efficacy across regions. Advanced therapies for IBD appear to be effective in Latin American populations, with clinical outcomes comparable to those reported globally. Increasing access to these treatments may improve patient outcomes, reduce disease burden, and potentially decrease long-term healthcare costs in the region.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.